[1] Fang K, Yang Q, Lin Y, et al. Global cirrhosis prevalence trends and attributable risk factors-an ecological study using data from 1990-2019[J]. Liver Int, 2022,42(12):2791-2799.
[2] Sigrist RMS, Liau J, Kaffas AE, et al. Ultrasound Elastography: Review of Techniques and Clinical Applications[J]. Theranostics, 2017,7(5):1303-1329.
[3] Obrzut M, Atamaniuk V, Obrzut B, et al. Normative values for magnetic resonance elastography-based liver stiffness in a healthy population[J]. Pol Arch Intern Med, 2019,129(5):321-326.
[4] QIBA Profile:Magnetic Resonance Elastography of the Liver - Google 学术搜索[EB/OL]. [2023-04-12]. https://xs.zidianzhan.net/scholar?q=QIBA+Profile%3AMagnetic+Resonance+Elastography+of+the+Liver.
[5] Yin M, Talwalkar J A, Glaser KJ, et al. Dynamic postprandial hepatic stiffness augmentation assessed with MR elastography in patients with chronic liver disease[J]. AJR Am J Roentgenol, 2011,197(1):64-70.
[6] Obrzut M, Atamaniuk V, Chen J, et al. Postprandial hepatic stiffness changes on magnetic resonance elastography in [J]. Sci Rep, 2021,11(1):19786.
[7] Wagner M, Corcuera-Solano I, Lo G, et al. Technical Failure of MR Elastography Examinations of the Liver: Experience from a Large Single-Center Study[J]. Radiology, 2017,284(2):401-412.
[8] Pepin KM, Welle CL, Guglielmo FF, et al. Magnetic resonance elastography of the liver: everything you need to know to get started[J]. Abdom Radiol(New York), 2022,47(1):94-114.
[9] Choi SL, Lee ES, Ko A, et al. Technical success rates and reliability of spin-echo echo-planar imaging (SE-EPI) MR elastography in patients with chronic liver disease or liver cirrhosis[J]. Eur Radiol, 2020,30(3):1730-1737.
[10] Abe K, Takahashi A, Imaizumi H, et al. Utility of magnetic resonance elastography for predicting ascites in patients [J]. J Gastroenterol Hepatol, 2018,33(3):733-740.
[11] Plaikner M, Kremser C, Zoller H, et al. Does gadoxetate disodium affect MRE measurements in the delayed hepatobiliary phase?[J]. Eur Radiol, 2019,29(2):829-837.
[12] Kim DW, Kim SY, Yoon HM, et al. Comparison of technical failure of MR elastography for measuring liver stiffness [J]. J Magn Reson Imaging, 2020,51(4):1086-1102.
[13] Chang W, Lee JM, Yoon JH, et al. Liver Fibrosis Staging with MR Elastography: Comparison of Diagnostic Performance between Patients with Chronic Hepatitis B and Those with Other Etiologic Causes[J].Radiology, 2016,280(1):88-97.
[14] Lim JK, Flamm SL, Singh S, et al. American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis[J]. Gastroenterology, 2017,152(6):1536-1543.
[15] Gidener T, Yin M, Dierkhising RA, et al. Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: A retrospective study[J]. Hepatology, 2022,75(2):379-390.
[16] Selvaraj EA, Mózes FE, Jayaswal ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients [J]. J Hepatol, 2021,75(4):770-785.
[17] Loomba R, Neuschwander-Tetri BA, Sanyal A, et al. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH[J]. 2020,72(4):1219-1229.
[18] Ferraioli G, Roccarina D. Update on the role of elastography in liver disease[J]. Ther Adv Gastroenter, 2022,15:1098323633.
[19] 彭泽, 冉旭, 陈路增, 等. 声辐射力脉冲技术测量肝脏弹性值的影响因素分析[J]. 中国超声医学杂志, 2017,33(07):604-608.
[20] 赵帆, 赵娟, 陈静, 等. Fibroscan和ARFI对慢性乙型肝炎肝纤维化诊断价值比较[J]. 中国肝脏病杂志(电子版), 2019,11(02):71-75.
[21] 孔梦娟, 周贤, 罗小庆. ARFI与Fibroscan评估HCV肝纤维化诊断效能的Meta分析[J]. 浙江医学, 2019,41(08):795-801.
[22] 张荣荣, 周瑾, 赵鹏, 等. 剪切波弹性成像与血清肝纤维化指标无创评估慢性乙型肝炎患者肝纤维化效能比较[J]. 肝脏, 2021,26(03):255-258.
[23] 张大鹍, 陈敏, 张文辉, 等. 声辐射力脉冲弹性成像技术预测肝硬化食管静脉曲张破裂出血的临床价值[J]. 临床肝胆病杂志, 2020,36(03):561-564.
[24] 李娜, 张渝, 赵丽军. FibroScan检测肝脏硬度和肝脂肪变性的影响因素研究进展[J]. 广东医学, 2021,42(05):612-615.
[25] Ng YZ, Lai LL, Wong SW, et al. Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease[J].PLoS One,2021,16(5):e0250300
[26] 代炼, 王左, 张海宇, 等. FibroScan与FibroTouch对肝脏硬度及脂肪定量的检测效能对比研究[J]. 湖南师范大学学报(医学版), 2020,17(01):94-98.
[27] 王民, 罗文萍, 张冠华, 等. FibroTouch、FibroScan及ARFI在原发性胆汁性胆管炎相关肝纤维化中的诊断价值[J]. 临床肝胆病杂志, 2021,37(04):817-822.
[28] Rasmussen D N, Thiele M, Johansen S, et al. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease[J]. J Hepatol, 2021,75(5):1017-1025.
[29] Boursier J, Hagstr?m H, Ekstedt M, et al. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events[J]. J Hepatol, 2022,76(5):1013-1020.
[30] Corpechot C, Carrat F, Gaouar F, et al. Liver stiffness measurement by vibration-controlled transient elastography [J]. J Hepatol, 2022,77(6):1545-1553.
[31] Houot M, Ngo Y, Munteanu M, et al. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B[J]. Aliment Pharmacol Ther, 2016,43(1):16-29.
[32] Poynard T, Lassailly G, Diaz E, et al. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data[J]. PLoS one, 2012,7(3):e30325.
[33] Thiele M, Madsen BS, Hansen JF, et al. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease[J]. Gastroenterology, 2018,154(5):1369-1379.
[34] Munteanu M, Pais R, Peta V, et al. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease[J]. Aliment Pharmacol Ther,2018,48(10):1117-1127.
[35] Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease[EB/OL]. [2023-04-12]. https://www.mdpi.com/2075-4418/11/1/98.
[36] Ballestri S, Mantovani A, Baldelli E, et al. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease[J]. Diagnostics (Basel, Switzerland), 2021,11(1):98.
[37] Liu X, Li H, Wei L, et al. Optimized cutoffs of gamma-glutamyl transpeptidase-to-platelet ratio, aspartate aminotransferase-to-platelet ratio index, and fibrosis-4 scoring systems for exclusion of cirrhosis in patients with chronic hepatitis B[J]. Hepatol Commun, 2022,6(7):1664-1672.
[38] 徐强, 郭峰, 王晓波, 等. 肝纤维化无创检测指标对肝硬化代偿期患者食管静脉曲张的预测价值[J]. 中西医结合肝病杂志, 2021,31(11):983-986.
[39] Zhang C, Wu J, Xu J, et al. Association between Aspartate Aminotransferase-to-Platelet Ratio Index and [J]. Dis Markers, 2019,2019:2046825.
[40] 周新兰, 王雁冰, 陆伟, 等. 5种血清无创模型对慢性乙型肝炎肝纤维化分期诊断价值的比较[J]. 临床肝胆病杂志, 2021,37(07):1567-1571.
[41] 刀辰冉, 陈义发, 阿力木江·买合木提, 等. S指数对符合米兰标准的肝癌合并慢性乙肝患者术后预后的预测价值[J]. 中华肝脏外科手术学电子杂志, 2021,10(03):274-278.
[42] Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant [J]. Gut, 2016,65(8):1369-1376.
[43] Milas GP, Karageorgiou V, Cholongitas E. Red cell distribution width to platelet ratio for liver fibrosis: a systematic [J]. Exp Rev Gastroenterol Hepatol, 2019,13(9):877-891.
[44] 林小钰, 胡晓敏, 陈永鹏. 无创肝纤维化指标对肝硬化患者高风险胃食管静脉曲张的预测价值[J]. 临床肝胆病杂志, 2020,36(08):1742-1746.
[45] 张鑫, 朱桂娟, 叶晓航, 等. GPR参数模型联合Fibroscan对慢性乙型肝炎肝纤维化的诊断效能[J]. 肝脏, 2022,27(08):877-880.
[46] Mendoza YP, Shengir M, Bosch J, et al. FIB-4 Improves LSM-Based Prediction of Complications in Overweight or Obese [J]. Clin Gastroenterol Hepatol, 2022,20(10):2396-2398.
[47] Inada K, Tamaki N, Kurosaki M, et al. Validation of magnetic resonance elastography plus fibrosis-4 for significant [J]. J Gastroenterology Hepatol, 2022,37(9):1726-1731.
[48] 马晓辉, 张新, 游云, 等. APRI、FIB-4联合对慢性乙型肝炎患者显著肝纤维化的诊断价值[J]. 胃肠病学, 2017,22(09):544-547. |
